Richard J Travers
Overview
Explore the profile of Richard J Travers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sedzro J, Smith S, Scott A, Wang Y, Travers R, Hemp R, et al.
Res Pract Thromb Haemost
. 2024 Sep;
8(6):102550.
PMID: 39309228
Background: Inorganic polyphosphates (polyPs) are linear chains of phosphates that accelerate blood clotting. Targeting polyP has been shown to reduce thrombosis. Objectives: To identify and characterize anti-polyP monoclonal antibodies that...
2.
Camarda N, Lu Q, Meola D, Man J, Song Z, Travers R, et al.
Clin Sci (Lond)
. 2024 Sep;
138(18):1131-1150.
PMID: 39282930
Vascular endothelial growth factor receptor inhibitors (VEGFRis) improve cancer survival but are associated with treatment-limiting hypertension, often attributed to endothelial cell (EC) dysfunction. Using phosphoproteomic profiling of VEGFRi-treated ECs, drugs...
3.
Travers R, Stepanian A, Jaffe I
Arterioscler Thromb Vasc Biol
. 2024 Aug;
44(10):2143-2153.
PMID: 39145393
Kinase inhibitors (KIs) targeting oncogenic molecular pathways have revolutionized cancer therapy. By directly targeting specific tumor-driving kinases, targeted therapies have fewer side effects compared with chemotherapy. Despite the enhanced specificity,...
4.
Wang Y, Travers R, Farrell A, Lu Q, Bays J, Stepanian A, et al.
PLoS One
. 2023 Nov;
18(11):e0294438.
PMID: 37983208
BCR-ABL tyrosine kinase inhibitors (TKIs) have dramatically improved survival in Philadelphia chromosome-positive leukemias. Newer BCR-ABL TKIs provide superior cancer outcomes but with increased risk of acute arterial thrombosis, which further...
5.
Cines D, Yarovoi S, Zaitsev S, Lebedeva T, Rauova L, Poncz M, et al.
Blood Adv
. 2018 Jan;
1(1):62-74.
PMID: 29296696
Heparin-induced thrombocytopenia (HIT) is a thrombotic disorder initiated by antibodies to complexes between platelet factor 4 (PF4) and heparin. The risk of recurrent thromboembolism persists after heparin is cleared and...
6.
Wijeyewickrema L, Lameignere E, Hor L, Duncan R, Shiba T, Travers R, et al.
Blood
. 2016 Jun;
128(13):1766-76.
PMID: 27338096
The complement system plays a key role in innate immunity, inflammation, and coagulation. The system is delicately balanced by negative regulatory mechanisms that modulate the host response to pathogen invasion...
7.
Zhu S, Travers R, Morrissey J, Diamond S
Blood
. 2015 Jul;
126(12):1494-502.
PMID: 26136249
Factor XIIa (FXIIa) and factor XIa (FXIa) contribute to thrombosis in animal models, whereas platelet-derived polyphosphate (polyP) may potentiate contact or thrombin-feedback pathways. The significance of these mediators in human...
8.
Smith S, Travers R, Morrissey J
Crit Rev Biochem Mol Biol
. 2015 May;
50(4):326-36.
PMID: 26018600
The plasma coagulation system in mammalian blood consists of a cascade of enzyme activation events in which serine proteases activate the proteins (proenzymes and procofactors) in the next step of...
9.
Shenoi R, Kalathottukaren M, Travers R, Lai B, Creagh A, Lange D, et al.
Sci Transl Med
. 2014 Oct;
6(260):260ra150.
PMID: 25355700
Heparin-based anticoagulant drugs have been widely used for the prevention of blood clotting during surgical procedures and for the treatment of thromboembolic events. However, bleeding risks associated with these anticoagulants...
10.
Travers R, Shenoi R, Kalathottukaren M, Kizhakkedathu J, Morrissey J
Blood
. 2014 Sep;
124(22):3183-90.
PMID: 25202141
Polyphosphate (polyP) is secreted by activated platelets and has been shown to contribute to thrombosis, suggesting that it could be a novel antithrombotic target. Previously reported polyP inhibitors based on...